Genetic Testing for Breast Cancer Risk (CME)

Original Release: June 26, 2015
Renewal Date: July 1, 2023
Expiration Date: June 30, 2026

Learning Objectives

• Determine appropriateness of breast cancer genetic testing
• Communicate the benefits, risks and limitations of genetic testing for breast cancer risk

Target Audience
Practicing primary care providers as well as students and residents.

Accreditation

The University of Connecticut School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Connecticut School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Conflict of Interest Policy
All faculty members participating in CME activities sponsored by the University of Connecticut School of Medicine are required to disclose to the program audience any actual or apparent conflict of interest related to the content of their presentations. Program planners have an obligation to resolve any actual conflicts of interest and share with the audience any safeguards put in place to prevent commercial bias from influencing the content. 

• Emily Edelman, MS, CGC – The Jackson Laboratory 
• Therese Ingram, MA – The Jackson Laboratory 
• Kalisi Logan, MS, CGC – The Jackson Laboratory 
• Kate Reed, MPH, ScM, CGC – The Jackson Laboratory 
• Linda Steinmark, MS, CGC – The Jackson Laboratory 
• Hayley Dunnack Yackel, PhD, RN, CMSRN, OCN – Hartford Healthcare Cancer Institute 
• Fatima Amir, MS, CGC - Genome Medical 

Disclosure Statement

The activity director, the co-activity director, planning committee, writers and reviewers for this educational event have no relevant financial relationship(s) with any ineligible companies that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation that needs to be disclosed. This educational event will not be discussing the off-labeled or investigational use of any product or device.

Actors are being used in this program and are presenting information that has been scripted for them. They were not involved with the educational content of this activity.

Commercial Support
This CME activity has no commercial support associated with it.

References

American College of Obstetricians and Gynecologists. Committee Opinion No. 793: Hereditary Cancer Syndromes and Risk Assessment. Obstetrics & Gynecology. 2019; 134(6):e143-e149.

Berliner JL, Cummings SA, Boldt Burnett B, Ricker CN. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors. J Genet Couns. 2021; 30(2):342-360.

Buys SS, Sandbach JF, Gammon A, et al. A Study of Over 35,000 Women with Breast Cancer Tested with a 25-Gene Panel of Hereditary Cancer Genes. Cancer. 2017; 123(10):1721-1730.

Couch FJ, Shimelis H, Hu C, et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017; 3(9):1190-.

Desmond A, Kurian AW, Gabree M, et al. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncol. 2015; 1(7):943-.

Kurian AW, Hare EE, Mills MA, et al. Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. JCO. 2014; 32(19):2001-2009.

Lee K, Seifert BA, Shimelis H, et al. Clinical Validity Assessment of Genes Frequently Tested on Hereditary Breast and Ovarian Cancer Susceptibility Sequencing Panels. Genet Med. 2018; 21(7):1497-1506.

Lundy MG, Forman A, Valverde K, Kessler L. An Investigation of Genetic Counselors’ Testing Recommendations: Pedigree Analysis and the Use of Multiplex Breast Cancer Panel Testing. J Genet Counsel. 2014; 23(4):618-632.

National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Detection, Prevention and Risk Reduction. (Requires free registration).

Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. JCO. 2015; 33(31):3660-3667.

Theobald KA, Susswein LR, Marshall ML, et al. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis. Ann Surg Oncol. 2018; 25(12):3556-3562.